Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Photocalorespirometry (Photo-CR): A Novel Method for Access to Photosynthetic Energy Conversion Efficiency.

Maskow T, Rothe A, Jakob T, Paufler S, Wilhelm C.

Sci Rep. 2019 Jun 26;9(1):9298. doi: 10.1038/s41598-019-45296-8.

2.

Variation of Donor and Acceptor Strength in Analogues of Brooker's Merocyanine and Generalization to Various Classes of Charge Transfer Compounds.

Dekhtyar M, Rettig W, Rothe A, Kurdyukov V, Tolmachev A.

J Phys Chem A. 2019 Apr 4;123(13):2694-2708. doi: 10.1021/acs.jpca.8b10660. Epub 2019 Mar 18.

PMID:
30821986
3.

Successful structure learning from observational data.

Rothe A, Deverett B, Mayrhofer R, Kemp C.

Cognition. 2018 Oct;179:266-297. doi: 10.1016/j.cognition.2018.06.003. Epub 2018 Jul 2.

PMID:
30064655
4.

Human gastric cancer modelling using organoids.

Seidlitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Grützmann K, Sommer U, Schweitzer C, Schölch S, Uhlemann H, Gaebler AM, Werner K, Krause M, Baretton GB, Welsch T, Koo BK, Aust DE, Klink B, Weitz J, Stange DE.

Gut. 2019 Feb;68(2):207-217. doi: 10.1136/gutjnl-2017-314549. Epub 2018 Apr 27.

5.

Mixed adenoneuroendocrine carcinoma of the ampulla of Vater: A case report.

Max N, Rothe A, Langner C.

Mol Clin Oncol. 2016 Jul;5(1):95-98. Epub 2016 Apr 14.

6.

Old World megadroughts and pluvials during the Common Era.

Cook ER, Seager R, Kushnir Y, Briffa KR, Büntgen U, Frank D, Krusic PJ, Tegel W, van der Schrier G, Andreu-Hayles L, Baillie M, Baittinger C, Bleicher N, Bonde N, Brown D, Carrer M, Cooper R, Čufar K, Dittmar C, Esper J, Griggs C, Gunnarson B, Günther B, Gutierrez E, Haneca K, Helama S, Herzig F, Heussner KU, Hofmann J, Janda P, Kontic R, Köse N, Kyncl T, Levanič T, Linderholm H, Manning S, Melvin TM, Miles D, Neuwirth B, Nicolussi K, Nola P, Panayotov M, Popa I, Rothe A, Seftigen K, Seim A, Svarva H, Svoboda M, Thun T, Timonen M, Touchan R, Trotsiuk V, Trouet V, Walder F, Ważny T, Wilson R, Zang C.

Sci Adv. 2015 Nov 6;1(10):e1500561. doi: 10.1126/sciadv.1500561. eCollection 2015 Nov.

7.

An Improved Instrument Table for Use in Functional Endoscopic Sinus Surgery.

Schmitz PM, Gollnick I, Modemann S, Rothe A, Niegsch R, Strauss G.

Med Sci Monit Basic Res. 2015 Jun 22;21:131-4. doi: 10.12659/MSMBR.894265.

8.

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A.

Blood. 2015 Jun 25;125(26):4024-31. doi: 10.1182/blood-2014-12-614636. Epub 2015 Apr 17.

9.

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J.

Oncotarget. 2015 Apr 30;6(12):10577-85.

10.

Uniform climate sensitivity in tree-ring stable isotopes across species and sites in a mid-latitude temperate forest.

Hartl-Meier C, Zang C, Büntgen U, Esper J, Rothe A, Göttlein A, Dirnböck T, Treydte K.

Tree Physiol. 2015 Jan;35(1):4-15. doi: 10.1093/treephys/tpu096. Epub 2014 Dec 2.

PMID:
25466725
11.

Molecular characterization of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patient.

Jancuskova T, Plachy R, Zemankova L, Hardekopf DW, Stika J, Zejskova L, Praulich I, Kreuzer KA, Rothe A, Othman MA, Kosyakova N, Pekova S.

Mol Cytogenet. 2014 Jul 15;7:47. doi: 10.1186/1755-8166-7-47. eCollection 2014.

12.

Patterns of drought tolerance in major European temperate forest trees: climatic drivers and levels of variability.

Zang C, Hartl-Meier C, Dittmar C, Rothe A, Menzel A.

Glob Chang Biol. 2014 Dec;20(12):3767-79. doi: 10.1111/gcb.12637. Epub 2014 Jun 14.

PMID:
24838398
13.

Warmed, humidified carbon dioxide insufflation versus standard carbon dioxide in laparoscopic cholecystectomy: a double-blinded randomized controlled trial.

Klugsberger B, Schreiner M, Rothe A, Haas D, Oppelt P, Shamiyeh A.

Surg Endosc. 2014 Sep;28(9):2656-60. doi: 10.1007/s00464-014-3522-x. Epub 2014 Apr 23.

PMID:
24756487
14.

Multi-specific antibodies for cancer immunotherapy.

Jachimowicz RD, Borchmann S, Rothe A.

BioDrugs. 2014 Aug;28(4):331-43. doi: 10.1007/s40259-014-0091-4. Review.

PMID:
24638872
15.

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, Klimm B, Diehl V, Sasse S, Rothe A, Fuchs M, Böll B, von Tresckow B, Borchmann P, Engert A.

Blood. 2014 Mar 13;123(11):1658-64. doi: 10.1182/blood-2013-07-512657. Epub 2014 Jan 29.

16.

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.

Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Keßler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, Borchmann P, Yazaki P, Koslowsky TC, Engert A, Heukamp LC, Hallek M, von Strandmann EP.

Int J Cancer. 2014 Jun 15;134(12):2829-40. doi: 10.1002/ijc.28609. Epub 2013 Nov 29.

17.

CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity.

Theurich S, Wennhold K, Wedemeyer I, Rothe A, Hübel K, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Scheid C, von Bergwelt-Baildon M.

Transplantation. 2013 Aug 15;96(3):e16-8. doi: 10.1097/TP.0b013e31829a9258. No abstract available.

PMID:
23917689
18.

18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.

Kahraman D, Theurich S, Rothe A, Kuhnert G, Sasse S, Scheid C, Dietlein M, Drzezga A, von Bergwelt-Baildon M, Kobe C.

Leuk Lymphoma. 2014 Apr;55(4):811-6. doi: 10.3109/10428194.2013.819575. Epub 2013 Jul 29.

PMID:
23805904
19.

Monoclonal antibody treatments for rheumatoid arthritis.

Bossaller L, Rothe A.

Expert Opin Biol Ther. 2013 Sep;13(9):1257-72. doi: 10.1517/14712598.2013.811230. Epub 2013 Jun 21. Review.

PMID:
23789825
20.

Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis.

Theurich S, Fischmann H, Chakupurakal G, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Rothe A, Scheid C, Hallek M, Skoetz N, von Bergwelt-Baildon M.

Crit Rev Oncol Hematol. 2013 Oct;88(1):178-86. doi: 10.1016/j.critrevonc.2013.03.009. Epub 2013 Apr 2. Review.

PMID:
23561334
21.

ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.

Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P.

J Clin Oncol. 2013 Apr 20;31(12):1522-9. doi: 10.1200/JCO.2012.45.4181. Epub 2013 Mar 18.

PMID:
23509310
22.

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.

Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hucke C, Köhl U, Dürkop H, Engert A, von Strandmann EP.

Mol Ther. 2013 Apr;21(4):895-903. doi: 10.1038/mt.2013.14. Epub 2013 Mar 5.

23.

Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.

Sasse S, Rothe A, Goergen H, Eichenauer DA, Lohri A, Kreher S, Jäger U, Bangard C, Kuhnert G, Böll B, von Tresckow B, Engert A.

Leuk Lymphoma. 2013 Oct;54(10):2144-8. doi: 10.3109/10428194.2013.775434. Epub 2013 Mar 27.

PMID:
23402268
24.

[Practice management - receptionist personnel - jack-of-all-trades, what else?].

Rothe Av.

Aktuelle Urol. 2013 Jan;44(1):21-4. doi: 10.1055/s-0033-1334842. Epub 2013 Feb 6. German. No abstract available.

PMID:
23389912
25.

The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2.

Shimabukuro-Vornhagen A, Draube A, Liebig T, Popov A, Rothe A, von Bergwelt-Baildon M.

Oncol Rep. 2013 Mar;29(3):1061-5. doi: 10.3892/or.2012.2215. Epub 2012 Dec 28.

PMID:
23292511
26.

Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.

Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jäger U, Bangard C, Böll B, von Bergwelt Baildon M, Theurich S, Borchmann P, Engert A.

Blood. 2012 Aug 16;120(7):1470-2. doi: 10.1182/blood-2012-05-430918. Epub 2012 Jul 11. Erratum in: Blood. 2014 Aug 14;124(7):1201.

27.

Cognitive anthropologists: who needs them?

Rothe A.

Top Cogn Sci. 2012 Jul;4(3):387-95. doi: 10.1111/j.1756-8765.2012.01198.x. Epub 2012 Jun 8.

28.

The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells.

Shimabukuro-Vornhagen A, Draube A, Liebig TM, Rothe A, Kochanek M, von Bergwelt-Baildon MS.

J Exp Clin Cancer Res. 2012 May 16;31:47. doi: 10.1186/1756-9966-31-47.

29.

Increased spatial salience in the social Simon task: a response-coding account of spatial compatibility effects.

Dittrich K, Rothe A, Klauer KC.

Atten Percept Psychophys. 2012 Jul;74(5):911-29. doi: 10.3758/s13414-012-0304-1.

PMID:
22528612
30.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J.

Blood. 2012 Jul 19;120(3):560-8. doi: 10.1182/blood-2011-12-397893. Epub 2012 Apr 17.

31.

Classification of skin sensitizing substances: a comparison between approaches used by the DFG-MAK Commission and the European Union legislation.

Lessmann H, Uter W, Diepgen TL, Drexler H, Fartasch M, Greim H, Hartwig A, Kreis P, Löser E, Merget R, Merk H, Nowak D, Rothe A, Stropp G, Schnuch A.

Regul Toxicol Pharmacol. 2011 Oct;61(1):1-8. doi: 10.1016/j.yrtph.2011.06.008. Epub 2011 Jul 21.

PMID:
21798301
32.

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report.

Shimabukuro-Vornhagen A, Rothe A, Nogova L, Kochanek M, Scheid C, von Bergwelt-Baildon M.

J Med Case Rep. 2011 May 30;5:215. doi: 10.1186/1752-1947-5-215.

33.

Successful reversal of life threatening cardiac effect following dosulepin overdose using intravenous lipid emulsion.

Boegevig S, Rothe A, Tfelt-Hansen J, Hoegberg LC.

Clin Toxicol (Phila). 2011 Apr;49(4):337-9. doi: 10.3109/15563650.2011.566880.

PMID:
21563912
34.

Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.

Jachimowicz RD, Fracasso G, Yazaki PJ, Power BE, Borchmann P, Engert A, Hansen HP, Reiners KS, Marie M, von Strandmann EP, Rothe A.

Mol Cancer Ther. 2011 Jun;10(6):1036-45. doi: 10.1158/1535-7163.MCT-10-1093. Epub 2011 Apr 27.

35.

Recombinant proteins in rheumatology - recent advances.

Rothe A, Rubbert A.

N Biotechnol. 2011 Sep;28(5):502-10. doi: 10.1016/j.nbt.2011.03.019. Epub 2011 Apr 5. Review.

PMID:
21473939
36.

10 years quality assurance of the dermatologist's procedure. ABD review board part II: 2003-2009.

Voss H, Elsner P, Fartasch M, Köllner A, Richter G, Rothe A, Schindera I, Schwanitz HJ, Skudlik C, Stary A, Wehrmann W, Worm M, John SM.

J Dtsch Dermatol Ges. 2011 Jan;9(1):42-6. doi: 10.1111/j.1610-0387.2010.07506.x. Epub 2010 Sep 2. English, German.

PMID:
20825529
37.

Exercise increases interleukin-10 levels both intraarticularly and peri-synovially in patients with knee osteoarthritis: a randomized controlled trial.

Helmark IC, Mikkelsen UR, Børglum J, Rothe A, Petersen MC, Andersen O, Langberg H, Kjaer M.

Arthritis Res Ther. 2010;12(4):R126. doi: 10.1186/ar3064. Epub 2010 Jul 1.

38.

Therapeutic advances in rheumatology with the use of recombinant proteins.

Rothe A, Power BE, Hudson PJ.

Nat Clin Pract Rheumatol. 2008 Nov;4(11):605-14. doi: 10.1038/ncprheum0909. Epub 2008 Sep 23. Review.

PMID:
18813220
39.

Responses to iron limitation in Hordeum vulgare L. as affected by the atmospheric CO2 concentration.

Haase S, Rothe A, Kania A, Wasaki J, Römheld V, Engels C, Kandeler E, Neumann G.

J Environ Qual. 2008 May 2;37(3):1254-62. doi: 10.2134/jeq2006.0136. Print 2008 May-Jun.

PMID:
18453445
40.

Ribosome display and selection of human anti-cD22 scFvs derived from an acute lymphocytic leukemia patient.

Rothe A, Nathanielsz A, Oberhäuser F, von Pogge SE, Engert A, Hudson PJ, Power BE.

Biol Chem. 2008 Apr;389(4):433-9. doi: 10.1515/BC.2008.045.

PMID:
18225987
41.

Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.

Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri VL, Borchmann P, McKinnon PJ, Hallek M, Engert A.

Immunity. 2007 Dec;27(6):965-74. Epub 2007 Dec 6.

42.

Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome display.

Rothe A, Nathanielsz A, Hosse RJ, Oberhäuser F, Strandmann EP, Engert A, Hudson PJ, Power BE.

J Biotechnol. 2007 Jul 15;130(4):448-54. Epub 2007 May 24.

PMID:
17604868
43.

Novel proteins in emulsions using in vitro compartmentalization.

Rothe A, Surjadi RN, Power BE.

Trends Biotechnol. 2006 Dec;24(12):587-92. Epub 2006 Oct 19. Review.

PMID:
17055094
44.

In vitro display technologies reveal novel biopharmaceutics.

Rothe A, Hosse RJ, Power BE.

FASEB J. 2006 Aug;20(10):1599-610.

PMID:
16873883
45.

Ribosome display for improved biotherapeutic molecules.

Rothe A, Hosse RJ, Power BE.

Expert Opin Biol Ther. 2006 Feb;6(2):177-87. Review.

PMID:
16436043
46.

A new generation of protein display scaffolds for molecular recognition.

Hosse RJ, Rothe A, Power BE.

Protein Sci. 2006 Jan;15(1):14-27. Review.

47.

[Four years of quality assurance of dermatologic procedures: report from the ABD clearing institution].

John SM, Diepgen TL, Elsner P, Köllner A, Richter G, Rothe A, Schindera I, Stary A, Wehrmann W, Schwanitz HJ.

J Dtsch Dermatol Ges. 2004 Aug;2(8):717-21. German.

PMID:
16279239
48.

Root exudation, phosphorus acquisition, and microbial diversity in the rhizosphere of white lupine as affected by phosphorus supply and atmospheric carbon dioxide concentration.

Wasaki J, Rothe A, Kania A, Neumann G, Römheld V, Shinano T, Osaki M, Kandeler E.

J Environ Qual. 2005 Nov 7;34(6):2157-66. Print 2005 Nov-Dec.

PMID:
16275716
49.

Designation of substances as skin sensitizing chemicals: a reply.

Schnuch A, Lessmann H, Becker D, Diepgen TL, Drexler H, Erdmann S, Fartasch M, Greim H, Kricke-Helling P, Merget R, Merk H, Nowak D, Rothe A, Stropp G, Wallenstein G, Uter W.

Hum Exp Toxicol. 2005 Mar;24(3):157-9. No abstract available.

PMID:
15901055
50.

The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.

Böll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, Engert A, Pogge von Strandmann E.

Blood. 2005 Sep 1;106(5):1839-42. Epub 2005 May 5.

Supplemental Content

Support Center